---
title: "Capricor Theraputics Q4 revenue falls to zero, net loss widens"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/278939139.md"
datetime: "2026-03-12T20:31:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278939139.md)
  - [en](https://longbridge.com/en/news/278939139.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278939139.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/278939139.md) | [繁體中文](https://longbridge.com/zh-HK/news/278939139.md)


# Capricor Theraputics Q4 revenue falls to zero, net loss widens

)

Overview

-   U.S. biotech reported Q4 revenue of $0, down from prior year as milestone revenue fully recognized
-   Q4 net loss widened yr/yr on higher operating expenses
-   Company ended 2025 with $318 mln cash, expects runway through 2027

Outlook

-   Capricor expects cash balance to support operations through 2027
-   Company expanding manufacturing capacity in anticipation of potential Deramiocel approval

Result Drivers

-   REVENUE DECLINE - Co said Q4 revenue fell to zero as all milestone and upfront payments from Nippon Shinyaku were fully recognized by end-2024
-   Cash, cash equivalents and marketable securities totaled approximately $318.1 million as of December 31, 2025
-   HIGHER OPERATING EXPENSES - Co attributed increased Q4 operating expenses to ongoing clinical development, regulatory activities, and commercial launch preparations Company press release:

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

### Q4 EPS -$0.62

Q4 Net -$30.20

Income mln

Q4 Basic -$0.62

### EPS

### Q4 $29.20

Operatin mln

g

Expenses

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 10 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the biotechnology & medical research peer group is “buy”
-   Wall Street’s median 12-month price target for Capricor Therapeutics Inc is $50.00, about 48.9% above its March 11 closing price of $33.57 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### 相关股票

- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-CN/quote/LABU.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [Capricor Therap (CAPR.US)](https://longbridge.com/zh-CN/quote/CAPR.US.md)

## 相关资讯与研究

- [09:00 ETDelonix Bioworks Announces Initiation of Phase 1 First-in-Human Clinical Trial of a Next-Generation MenB OMV Vaccine DX-104](https://longbridge.com/zh-CN/news/281025352.md)
- [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/zh-CN/news/281024362.md)
- [Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA | CAPR Stock News](https://longbridge.com/zh-CN/news/278565215.md)
- [Teva Pharmaceutical Gets US FDA Approval for Prolia Biosimilar; Xoliar Biosimiliar Applications Accepted in US, Europe](https://longbridge.com/zh-CN/news/281026919.md)
- [Capricorn Energy Rejects Dragon Oil Bids for Western Desert Assets as Undervalued](https://longbridge.com/zh-CN/news/280347712.md)